XML 83 R63.htm IDEA: XBRL DOCUMENT v3.25.4
Out-Licensing Agreements (Details)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Aug. 31, 2022
USD ($)
item
Feb. 28, 2022
USD ($)
item
agreement
Mar. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Collaborative agreements                
Revenue         $ 677,564 $ 423,239 $ 270,259  
License and collaboration revenue                
Collaborative agreements                
Revenue           6,210 37,083  
Collaboration Agreements                
Collaborative agreements                
Upfront payments received   $ 22,000            
Number of agreements entered into | agreement   2            
Territory License - ARCALYST                
Collaborative agreements                
Upfront payments received   $ 12,000            
Addition to transaction price           20,000    
Number of performance obligations in an agreement | item   1            
Term of agreement for royalty payments   12 years            
Notice period to terminate the agreement   12 months            
Time period threshold of continuous material development or commercialization activities in China that, if not met, can trigger the right for the Company to terminate the agreement   6 months            
Notice period to terminate the agreement if there is no material development or commercialization activities with respect to the licensed product in China   60 days            
Territory License - ARCALYST | Maximum                
Collaborative agreements                
Payments to be received by the company upon the achievement of specified development, regulatory and sales milestones         50,000      
Territory License - ARCALYST | Non-current deferred revenue                
Collaborative agreements                
Transaction price         31,811      
Territory License - ARCALYST | License and collaboration revenue                
Collaborative agreements                
Revenue         0 189 0  
Territory License - Mavrilimumab                
Collaborative agreements                
Upfront payments received   $ 10,000            
Transaction price   $ 10,000            
Territory License - Mavrilimumab | License and collaboration revenue                
Collaborative agreements                
Revenue               $ 10,000
Worldwide License - Vixarelimab                
Collaborative agreements                
Upfront payments received $ 80,000              
Payments received upon delivery of certain materials             20,000  
Milestone receipts           5,000 15,000  
Addition to transaction price     $ 20,000 $ 20,000 5,000 10,000 25,000  
Number of performance obligations in an agreement | item 4              
Payments to be received by the company upon the achievement of specified development, regulatory and sales milestones         570,000      
Worldwide License - Vixarelimab | Maximum                
Collaborative agreements                
Payments to be received by the company upon the achievement of specified development, regulatory and sales milestones $ 600,000              
Worldwide License - Vixarelimab | License and collaboration revenue                
Collaborative agreements                
Revenue         $ 0 5,261 $ 37,083  
Revenue recognized related to performance obligations satisfied in prior periods           $ 4,989